Management of Hyperglycemia in STEMI Patients

Acute Phase Management

The American College of Cardiology recommends an insulin infusion for STEMI patients with hyperglycemia, targeting glucose levels ≤11.0 mmol/L (200 mg/dL) while avoiding hypoglycemia, in the first 24-48 hours 1, 2
Target blood glucose concentration should be maintained at ≤11.0 mmol/L (200 mg/dL) while absolutely avoiding hypoglycemia (defined as glucose <5 mmol/L or <90 mg/dL) 2
A dose-adjusted insulin infusion with frequent monitoring of glycemia is required 2
Routine glucose-insulin-potassium infusion is NOT indicated and may be potentially harmful 2

Hyperglycemia on admission is a powerful predictor of mortality and in-hospital complications in STEMI patients 3
Compelling evidence supports intensive insulin therapy to achieve normal blood glucose levels in critically ill patients 1

After the acute phase, individualize treatment selecting from a combination of insulin, insulin analogs, and oral hypoglycemic agents to achieve the best glycemic control 1
Measure HbA1c to assess long-term glucose control and guide ongoing management 2
Target HbA1c should be less than 7% 4

Before discharge, establish plans for optimal outpatient glucose control and secondary prevention 2
Measure fasting glucose and HbA1c, and consider post-discharge oral glucose tolerance test if not already performed 2
Address other cardiovascular risk factors (lipids, blood pressure, weight management, physical activity) 4

Avoid hypoglycemia (glucose <5 mmol/L or <90 mg/dL), which is associated with adverse outcomes 2
Recognize that diabetes management is just one component of comprehensive STEMI care, which should also include appropriate reperfusion therapy, antiplatelet agents, beta-blockers, and ACE inhibitors 4, 1